{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:32:07Z","timestamp":1776792727782,"version":"3.51.2"},"reference-count":26,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2483098","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T02:51:17Z","timestamp":1742871077000},"page":"460-470","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Cost-utility analysis of isavuconazole compared with the standard of care as a first-line therapy for patients with invasive fungal infection prior to differential pathogen diagnosis in Japan"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-6916","authenticated-orcid":false,"given":"Ataru","family":"Igarashi","sequence":"first","affiliation":[{"name":"Department of Health Policy and Public Health, Graduate School of Pharmaceutical Sciences, The University of Tokyo","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Inoue","sequence":"additional","affiliation":[{"name":"Asahi Kasei Pharma Corporation","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0032-6994","authenticated-orcid":false,"given":"Yasushi","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tohoku University Hospital","place":["Sendai, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.16-00010"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/590004"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152900"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ571"},{"key":"e_1_3_6_7_1","unstructured":"Cresemba (voriconazole) prescribing information. Tokyo: Pharmaceuticals and Medical Devices Agency; 2024 [cited 2024 Mar 5]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/100898_6179003M1021_1_01."},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00071-2"},{"key":"e_1_3_6_10_1","unstructured":"Vfend (voriconazole) Prescribing Information. Tokyo: pharmaceuticals and Medical Devices Agency; 2024 [cited 2024 March 5]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/672212_6179001F1023_3_09."},{"key":"e_1_3_6_11_1","volume-title":"Revised guidelines for therapeutic drug monitoring of antimicrobials","author":"Committee of Practice Guidelines for TDM of Antimicrobial Agents","year":"2022","unstructured":"Committee of Practice Guidelines for TDM of Antimicrobial Agents. Revised guidelines for therapeutic drug monitoring of antimicrobials. Tokyo: Japanese Society of Chemotherapy, The Japanese Society of Therapeutic Drug Monitoring; 2022."},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3683-2"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1638789"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13189"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1927691"},{"key":"e_1_3_6_16_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health National Institute of Public Health (C2H) (Japan). Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council (version 3.0). Saitama C2H; 2022 [cited 2024 March 5]. Available from: https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf."},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.56.J99"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1846510"},{"key":"e_1_3_6_19_1","unstructured":"accessdata.fda.gov. US: center For Drug Evaluation And Research [Internet]; July 2014 [cited 2024 Mar 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/207500Orig1207501Orig1s000MedR.pdf."},{"key":"e_1_3_6_20_1","unstructured":"2024 Drug pricing list. Tokyo: Ministry of Health Labour and Welfare; 2024 [cited 2024 March 15]. Available from: https:\/\/www.mhlw.go.jp\/content\/12404000\/001218724.pdf."},{"key":"e_1_3_6_21_1","unstructured":"The Survey on Medical Insurance Benefits. Tokyo: e-Stat; 2020 [cited 2024 March 15]. Available from: https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&layout=datalist&toukei=00450389&tstat=000001044924&cycle=0&tclass1=000001044945&tclass2=000001171146&stat_infid=000032251680&tclass3val=0."},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.137"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-50"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.3"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1481"},{"key":"e_1_3_6_26_1","unstructured":"digital.nhs.uk. UK: NHS Digital [Internet]; 2016\/2017 [cited 2019 Feb]. Available from: https:\/\/files.digital.nhs.uk\/publication\/7\/d\/hosp-epis-stat-admi-diag-2016-17-tab.xlsx."},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2007.140087"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2483098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:46:24Z","timestamp":1766400384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2483098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2483098"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2483098","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}